Concord Drugs Ltd. (CONCORD) — Tipsheet https://tipsheet.markets/company/concord/ Every Tipsheet Editorial note covering Concord Drugs Ltd. (CONCORD), newest first. Grounded in BSE/NSE primary-source filings. en-in Thu, 16 Jul 2026 03:12:34 GMT Concord Drugs doubles revenue, auditor flags ₹4.14 cr overdue receivables https://tipsheet.markets/concord-concord-drugs-doubles-revenue-auditor-flags-4-14-cr-overdue-receivables-100200/ https://tipsheet.markets/concord-concord-drugs-doubles-revenue-auditor-flags-4-14-cr-overdue-receivables-100200/ Wed, 27 May 2026 16:37:01 GMT Audited FY26 standalone revenue rose to ₹75.85 cr, but the auditor's emphasis of matter on long-overdue receivables is the real story. Audited FY26 standalone revenue rose to ₹75.85 cr, but the auditor's emphasis of matter on long-overdue receivables is the real story.

What’s new

  • Board approved audited FY26 results: standalone revenue rose to ₹75.85 cr from ₹36.93 cr.
  • Standalone net profit jumped to ₹1.04 cr from ₹0.30 cr in the prior year.
  • Auditor issued an emphasis of matter on ₹4.14 cr in long-overdue trade receivables.

Why it matters

For a nano-cap, doubling revenue is a material shift in scale. But the auditor's emphasis on ₹4.14 cr in overdue receivables, a sum nearly four times the full-year net profit, casts doubt on how much of that top-line growth converted to cash. The results themselves are not new information.

What we’re watching

  • Whether the overdue receivables are eventually written down.
  • If revenue growth can be sustained into FY27.
  • Cash flow from operations relative to the reported profit.

The full read

Concord Drugs' audited FY26 numbers show standalone revenue more than doubling to ₹75.85 crore from ₹36.93 crore, with net profit jumping to ₹1.04 crore from ₹0.30 crore. The results are not new. The more interesting disclosure is the auditor's emphasis of matter on ₹4.14 crore in long-overdue trade receivables. For a nano-cap, that sum is large and represents nearly four times the full-year net profit. Whether that cash eventually gets collected, or written off, will determine how much of the headline revenue growth translates to real value.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial Concord Drugs doubled revenue. The auditor flagged ₹4.14 cr with no provision. https://tipsheet.markets/concord-concord-drugs-doubled-revenue-the-auditor-flagged-4-14-cr-with-no-provision-100184/ https://tipsheet.markets/concord-concord-drugs-doubled-revenue-the-auditor-flagged-4-14-cr-with-no-provision-100184/ Wed, 27 May 2026 16:31:25 GMT Standalone sales surged 105% to ₹75.85 cr in FY26. But the auditor won't sign off on ₹4.14 cr in receivables over two years old. Standalone sales surged 105% to ₹75.85 cr in FY26. But the auditor won't sign off on ₹4.14 cr in receivables over two years old.

What’s new

  • Standalone revenue more than doubled to ₹75.85 cr, up 105% from ₹36.93 cr.
  • Net profit rose to ₹1.04 cr from ₹29.57 lakhs the prior year.
  • Auditor flagged ₹4.14 cr in receivables over two years old with no provision; some balances unconfirmed.

Why it matters

The top-line growth is a genuine step-change, but the auditor's note is a material red flag. The ₹4.14 crore in unprovisioned receivables is four times the company's full-year profit. A write-down would erase the year's earnings and question the quality of the revenue surge.

What we’re watching

  • Whether management makes a provision in the next quarter or contests the auditor.
  • If the unconfirmed balances are eventually collected or written off.
  • The standalone trajectory once the one-off consolidation effect of Proton Remedies normalizes.

The full read

Concord Drugs' revenue more than doubled. Standalone sales hit ₹75.85 crore in FY26, up 105% from ₹36.93 crore. Net profit climbed to ₹1.04 crore from just ₹29.57 lakhs. The company credits a sharp pick-up in pharma sales and the full consolidation of subsidiary Proton Remedies. But the auditor's report changes the story. Pundarikashyam and Associates flagged ₹4.14 crore in trade receivables outstanding for over two years with no provision made. That amount is four times the company's annual profit. The auditor also said some balances remain unconfirmed. The asset-quality question now overshadows the growth story. Hardly a clean close.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial